Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature
Information source: University Hospital, Basel, Switzerland
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Primary Vascular Dysregulation
Intervention: Brimonidine (Drug); Latanoprost (Drug); Placebo (Drug)
Sponsored by: University Hospital, Basel, Switzerland
Official(s) and/or principal investigator(s):
Josef Flammer, MD, Study Director, Affiliation: University of Basel, Dept. of Ophthalmology
It is already known that the local treatment with Alphagan eye drops (a drug commonly used
by glaucoma patients) reduces ocular blood flow. In-vitro studies suggest that the
vasoconstrictive effect of Alphagan is more pronounced when this drug is combined with a
prostaglandin analogue (eg. Xalatan eye drops). The investigators also question whether
this effect is more pronounced in subjects suffering from a primary vascular dysregulation
(PVD). To test for the effect of these drugs on PVD and non-PVD subjects the investigators
will take measurements of corneal temperature as surrogate for ocular blood flow.
Official title: Effect of Alphagan and Xalatan Eye Drops on Corneal Temperature
Study design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Corneal temperature
The investigators would like to investigate the effect of Alphagan eye drops, Xalatan eye
drops and their combination (both Alphagan and Xalatan) on corneal temperature in healthy
subjects with and without a primary vascular dysregulation (PVD).
The investigators would like to answer the following questions:
1. Do the individual drugs influence the circulation to the eye as quantified indirectly
via corneal temperature?
2. Does the combination of Alphagan and Xalatan give an additive or even potentiated
3. Is the sequence of application of drugs of relevance (Alphagan applied first, Xalatan
second, or vice versa)?
4. Do PVD and non-PVD subjects respond differently to these drugs?
20 healthy non-PVD subjects and 20 healthy PVD subjects in the age range from 20-40 years
will be recruited. Recruited subjects will have all measurements: corneal temperature,
intraocular pressure (IOP), ear temperature, blood-pressure. Both prior to and after
instillation of eye drops (Xalatan, Alphagan and placebo).
Minimum age: 18 Years.
Maximum age: 48 Years.
- age 18-48 years
- normal findings on ophthalmological examination
- history of ocular or systemic disease
- chronic or current systemic or topical medication
- drug or alcohol abuse
- art. hypertension
Locations and Contacts
University of Basel, Dept. of Ophthalmology, Basel 4031, Switzerland
Starting date: June 2011
Last updated: December 10, 2013